Major depressive disorder (MDD) was previously hypothesized to be a disease of
monoamine deficiency in which low levels of monoamines in the synaptic cleft were …

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Depression is a global threat to mental health that affects around 264 million people
worldwide. Despite the considerable evolution in our understanding of the pathophysiology …

Depression is a debilitating mental disorder that affects> 322 million people worldwide.
Despite the availability of several antidepressant agents, many patients remain treatment …

Highlights•Chronic stress, depression and inflammation have been consistently
linked.•Stress-induced inflammatory states can contribute to treatment resistance.•Ketamine …

Cognitive impairment has been observed in patients with various psychiatric disorders,
including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD) …

Recent evidence suggests that Alzheimer's disease (AD) and depression share common
mechanisms of pathogenesis. In particular, deregulation of glutamate-mediated excitatory …

Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine–Induced
Sustained Antidepressant-like Effects - Biological Psychiatry Skip to Main Content …

The gut microbiota has been increasingly correlated with depressive disorder. It was
recently shown that the transplantation of the gut microbiota from depressed patients to …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …